<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65483">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949038</url>
  </required_header>
  <id_info>
    <org_study_id>391009</org_study_id>
    <nct_id>NCT01949038</nct_id>
  </id_info>
  <brief_title>Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy</brief_title>
  <official_title>Comparison Between Sublingual and Oral Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnostic esophagogastroduodenoscopy is an uncomfortable and stressful procedure for most
      of the patients. Various methods are available for sedation during this procedure. Because
      of some side effects related to intravenous administration of sedatives, oral administration
      of these drugs is under attention. Alprazolam is a benzodiazepine which is used mainly in
      treatment of anxiety. Hence, we determine the efficacy of oral and sublingual alprazolam as
      for sedation during this procedure. We hypothesize that sublingual alprazolam is more
      effective than that oral form and both forms more effective than placebo in reducing anxiety
      and pain/discomfort related to the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Procedure related pain/discomfort</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Procedure related pain/discomfort is assessed by patients on a 11-point numeric rating scales after the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-procedure anxiety</measure>
    <time_frame>Before and 30 minutes after medication</time_frame>
    <safety_issue>No</safety_issue>
    <description>Procedure related anxiety is assessed by patients on a 11-point numeric rating scales before and 30 minutes after the medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Procedure related patients' satisfaction is assessed by patients on a 11-point numeric rating scales after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compliance is assessed by patients from no compliance (0) to excellent compliance (4) after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the procedure</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of the procedure is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Within the first one hour after the procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any side effects attributed to alprazolam is assessed Within the first one hour after the procedure.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Diagnostic Esophagogastroduodenoscopy</condition>
  <arm_group>
    <arm_group_label>Oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive one oral dose of placebo least 30 minutes before the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sublingual placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive one oral dose of placebo at least 30 minutes before the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sublingual alprazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral alprazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral alprazolam</intervention_name>
    <arm_group_label>Oral alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual alprazolam</intervention_name>
    <arm_group_label>Sublingual alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <arm_group_label>Oral placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual placebo</intervention_name>
    <arm_group_label>Sublingual placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referring for upper GI endoscopy

          -  Age 18 to 65 years

          -  First experience of upper GI endoscopy

          -  Class I or II of American Anesthesiology Association

          -  Willingness to participate

        Exclusion Criteria:

          -  Severe psychiatric, neurological, cardio-vascular, or renal disorders

          -  History of allergy or intolerance to benzodiazepines or lidocaine

          -  History of upper GI surgery

          -  Pregnancy or lactation

          -  GI anomalia during endoscopy

          -  Need for therapeutic procedures during endoscopy

          -  Active bleeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Shavakhi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Outpatient Clinic of Gastroenterology</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Hedenbro JL, Ekelund M, Aberg T, Lindblom A. Oral sedation for diagnostic upper endoscopy. Endoscopy. 1991 Jan;23(1):8-10.</citation>
    <PMID>2009843</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 16, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ali Gholamrezaei</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Discomfort</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Satisfaction</keyword>
  <keyword>Compliance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
